Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial Cancer : Episode 7
Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer
Drs Backes and Powell discuss the management of adverse events between upfront immunotherapy versus chemotherapy followed by later immunotherapy for endometrial cancer, noting the need for molecular subgroup data from trials like LEAP-001.
EP: 1.Recent Advances in Endometrial Cancer
EP: 2.Key Takeaways From the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting
EP: 3.Current Data on Single-Agent Immunotherapy in Advanced Endometrial Cancer
EP: 4.Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial
EP: 5.Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer
EP: 6.The Impact of Real-World Evidence on the Treatment of Patients With Advanced Endometrial Cancer
Now Viewing
EP: 7.Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer
EP: 8.The TROPiCS-03 Study: Sacituzumab Govitecan in Patients With Advanced Endometrial Cancer
EP: 9.Unmet Needs in the Management of Patients With Advanced Endometrial Cancer
EP: 10.Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer
Related Videos
Related Content
